Ikarian Capital’s Fulcrum Therapeutics FULC Stock Holding History

Ikarian Capital’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.84M	Hold	1,049,161	–	–	0.41%	68
2026 Q1	$8.05M	Sell	1,049,161 -326,311	-24%	-$3.03M	0.65%	43
2025 Q4	$15.6M	Buy	1,375,472 +86,247	+7%	+$878K	1.21%	23
2025 Q3	$11.9M	Buy	1,289,225 +860,704	+201%	+$6.23M	1.2%	21
2025 Q2	$2.95M	Buy	428,521 +228,425	+114%	+$1.22M	0.57%	54
2025 Q1	$576K	Hold	200,096	–	–	0.07%	112
2024 Q4	$940K	Buy	200,096 +125,096	+167%	+$462K	0.13%	110
2024 Q3	$268K	Buy	+75,000	New	+$556K	0.04%	133
2021 Q3	–	Sell	-162,700	Closed	-$1.71M	–	233
2021 Q2	$1.71M	Sell	162,700 -264,039	-62%	-$2.67M	0.14%	140
2021 Q1	$5.03M	Sell	426,739 -10,961	-3%	-$136K	0.17%	118
2020 Q4	$5.13M	Buy	+437,700	New	+$4.95M	0.23%	92

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital's FULC Position: Q2 2026 in Review

Ikarian Capital held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 1,049,161 shares worth $3.84M. The position accounts for 0.41% of the portfolio, ranked #68.

Ikarian Capital first reported a position in FULC in Q4 2020 and has held it in 11 quarters since. The position peaked at $15.6M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Ikarian Capital held 1,049,161 shares of Fulcrum Therapeutics worth $3.84M as of Q2 2026.
Ikarian Capital left its Fulcrum Therapeutics share count unchanged in Q2 2026.
Fulcrum Therapeutics made up 0.41% of Ikarian Capital's portfolio in Q2 2026, its #68 holding.
Ikarian Capital first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 11 quarters since.
Ikarian Capital's Fulcrum Therapeutics position peaked at $15.6M in Q4 2025.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.